Blog - Page 285 of 5680 - QualityStocks

TuesdayJul 29, 2025 9:45 am

QualityStocksNewsBreaks – Nightfood Holdings Inc. (OTCQB: NGTF) Subsidiary FHVH to Showcase Robotics and AI Solutions at California Restaurant Show

Nightfood Holdings (OTCQB: NGTF), through its wholly owned subsidiary Future Hospitality Ventures Holdings Inc. (FHVH) doing business as RoboOp365, announced its participation in the California Restaurant Show from Aug. 3–5, 2025, at the Anaheim Convention Center. Exhibiting at booth 228, FHVH will feature live demonstrations of its AI-enabled kitchen operations and introduce components of its proposed joint venture with Los Angeles Cooking School to create the first U.S. culinary education platform fully integrated with AI, robotics, and automation systems. CEO Sonny Wang said the initiative reflects FHVH’s next phase of execution as it expands its footprint in the $400+ billion…

TuesdayJul 29, 2025 9:35 am

QualityStocksNewsBreaks – Onar Holding Corporation (OTCQB: ONAR) Expands Strategic Partnership with IQSTEL (NASDAQ: IQST) to Launch AI-Driven Multi-Agentic Operating Infrastructure

Onar (OTCQB: ONAR), a marketing technology company and global agency network, announced an expanded partnership with IQSTEL, Inc. (NASDAQ: IQST) and its AI subsidiary Reality Border to develop a next-generation AI-driven, multi-agentic operating infrastructure. Building on ONAR’s 2024 rebranding of IQSTEL, the initiative will integrate dedicated AI agents for every ONAR employee and client account, streamlining operations, enhancing performance optimization, and enabling real-time strategic insights. CEO Claude Zdanow said the system amplifies human potential by automating repetitive processes while preserving data security. The three-phase rollout will introduce operational streamlining, strategic enablement, and creative augmentation, positioning ONAR at the forefront of…

TuesdayJul 29, 2025 9:25 am

QualityStocksNewsBreaks – Branded Legacy, Inc. (OTC: BLEG) Signs LOI to Acquire Bio-Legacy Evaluative Group and Expand Intranasal Drug Delivery Portfolio

Branded Legacy (OTC: BLEG), a diversified holdings company focused on health and wellness solutions, announced the execution of a non-binding Letter of Intent to acquire Bio-Legacy Evaluative Group, a pioneer in advanced intranasal drug delivery technologies. The proposed $1.5 million Preferred D stock transaction would transfer 100% of Bio-Legacy’s equity, assets, and IP, supporting Branded Legacy’s entry into high-growth markets for addiction treatments and vaccine accessibility. Bio-Legacy’s patented naloxone device addresses cost and dosing challenges in a market projected to exceed $1.16 billion by 2032. Following the closing, Bio-Legacy CEO Amin Janmohamed will assume the roles of CEO and Chairman of…

TuesdayJul 29, 2025 9:10 am

QualityStocksNewsBreaks – SEGG Media Corporation (NASDAQ: SEGG, LTRYW) Drivers Deliver Strong Results at Laguna Seca

SEGG Media (NASDAQ: SEGG, LTRYW), a technology company at the intersection of sports, entertainment and gaming, showcased its Sports.com and Lottery.com brands during the Java House Grand Prix of Monterey at WeatherTech Raceway Laguna Seca. Callum Ilott surged from P24 to finish P6, marking PREMA Racing’s best-ever NTT INDYCAR Series result. Louis Foster qualified P7, maintaining his streak of top-10 starts, while Sebastian Murray rebounded from an early setback with a career-best fifth-place finish in INDY NXT by Firestone, earning top honors for the Andretti fleet. SEGG Media Chairman and CEO Matthew McGahan said the exposure underscored the value promised…

TuesdayJul 29, 2025 9:00 am

QualityStocksNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Receives FDA Fast Track Designation for CLD-201 in Soft Tissue Sarcoma

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing targeted genetic medicine delivery therapies, announced that the U.S. Food and Drug Administration granted Fast Track designation to CLD-201 (SuperNova), its allogeneic adipose stem-cell loaded oncolytic virus for treating soft tissue sarcoma. The designation provides opportunities for expedited development, including priority review and accelerated approval. CLD-201, which received IND clearance in April, will enter a Phase 1 trial evaluating safety and efficacy in sarcoma, triple-negative breast cancer, and head and neck squamous cell carcinoma. Chief Medical Officer Guy Travis Clifton, M.D., said the milestone validates CLD-201’s potential to deliver durable,…

MondayJul 28, 2025 11:17 am

QualityStocksNewsBreaks – SEGG Media Corporation (NASDAQ: SEGG, LTRYW) Showcases Drivers at Laguna Seca Java House Grand Prix of Monterey

SEGG Media (NASDAQ: SEGG, LTRYW), a technology company at the intersection of sports, entertainment and gaming, announced that Lottery.com and Sports.com-sponsored drivers Callum Ilott, Louis Foster and Sebastian Murray will compete at the Java House Grand Prix of Monterey at WeatherTech Raceway Laguna Seca. Foster, driving the #45 Droplight Honda for Rahal Letterman Lanigan Racing, enters the event with an average starting position of 8.4 over the last five races and aims to convert his strong qualifying pace into points. Ilott returns to the circuit where he secured his career-best IndyCar finish of P5 in 2023, while Murray makes his…

MondayJul 28, 2025 11:00 am

QualityStocksNewsBreaks – Brera Holdings PLC (NASDAQ: BREA) Joins Exclusive Serie B Multi-Club Ownership Ranks, Juve Stabia Valuation Surges 245%

Brera Holdings (NASDAQ: BREA), an Ireland-based international holding company pursuing a multi-club ownership (MCO) strategy, has become the second MCO in Italy’s Serie B League alongside City Football Group, majority owned by Abu Dhabi United Group. Brera owns SS Juve Stabia, while City Group holds Palermo FC and Manchester City FC. Executive Chairman Daniel J. McClory said the Serie B owners’ meetings in Rome highlighted Brera’s integration into the league’s top ownership group. Juve Stabia, dubbed “The Second Team of Naples,” posted the highest market value increase in Serie B over the 2024-25 season, rising 245% to US$32 million from…

MondayJul 28, 2025 9:45 am

QualityStocksNewsBreaks – Bollinger Innovations, Inc. (NASDAQ: BINI) Completes Name and Ticker Change from Mullen Automotive

Bollinger Innovations (NASDAQ: BINI), an electric vehicle manufacturer, announced that its previously disclosed name change from Mullen Automotive Inc. to Bollinger Innovations, Inc. is effective as of July 28, 2025, along with its new Nasdaq stock symbol “BINI.” The company stated the transition unifies its commercial Class 1, 3 and 4 vehicles under a single brand identity. CEO and Chairman David Michery said the move marks the completion of the company’s brand evolution while having no impact on its legal structure or operations. No shareholder action is required as a result of the changes. To view the full press release,…

MondayJul 28, 2025 9:45 am

Platinum Group Metals Ltd. (NYSE American: PLG) (TSX: PTM) Highlights Rising Importance of Platinum in Electrical, Clean-Energy Applications

Platinum’s unique properties — exceptional conductivity, heat resistance and catalytic efficiency — make it indispensable across a range of electrical applications. Hydrogen fuel cells, particularly the proton exchange membrane variety, are one of the most promising sources of green energy production. PLG is a player in this emerging landscape, with a focus on the development of large-scale platinum group metal resources in the Bushveld Complex. As global industries search for scalable and sustainable energy solutions, platinum has emerged as a critical component in the future of electrical applications. Platinum Group Metals (NYSE American: PLG) (TSX: PTM), is well positioned to…

MondayJul 28, 2025 9:00 am

Clene Inc. (NASDAQ: CLNN) Offers Investors a Compelling Entry into the Growing ALS Market with Key FDA Milestones for Lead Drug Candidate

Clene is progressing toward a potential FDA accelerated approval for its ALS (Amyotrophic Lateral Sclerosis) drug CNM-Au8® in 2026, a market that is expected to reach $1.3 billion by 2034 with significant unmet need. Clene’s technology targets mitochondrial dysfunction, a novel approach to neurodegenerative diseases, and key FDA meetings in the coming months of 2025 could be major valuation catalysts for investors. Biomarker and survival data from over 150 patients will be critical to the company’s regulatory case and expects important NfL data in the fourth quarter of 2025. Clene is preparing to initiate a confirmatory Phase 3 ALS trial…

Site Search

Company Search